empoweringmuscleempoweringlives
Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function.
cardiovascular disease
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
NEUROMUSCULAR DISEASE
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
Press Releases
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
- Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Cytokinetics Corporate Presentation
Pipeline
We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, CK-274, CK-136 and CK-601.
Careers
We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.